The Pharmacogenetics Research Network: From SNP discovery to clinical drug response

K. M. Giacomini, C. M. Brett, R. B. Altman, N. L. Benowitz, M. E. Dolan, D. A. Flockhart, J. A. Johnson, D. F. Hayes, T. Klein, R. M. Krauss, D. L. Kroetz, H. L. McLeod, A. T. Nguyen, M. J. Ratain, M. V. Relling, V. Reus, D. M. Roden, C. A. Schaefer, A. R. Shuldiner, T. SkaarK. Tantisira, R. F. Tyndale, L. Wang, R. M. Weinshilboum, S. T. Weiss, I. Zineh

Research output: Contribution to journalReview articlepeer-review

191 Scopus citations


The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase II drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.

Original languageEnglish (US)
Pages (from-to)328-345
Number of pages18
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Mar 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'The Pharmacogenetics Research Network: From SNP discovery to clinical drug response'. Together they form a unique fingerprint.

Cite this